Sarepta Therapeutics, Inc.
EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
Status:
Application
Type:
Utility
Filling date:
22 Dec 2020
Issue date:
17 Jun 2021